Australia markets closed

AVXL Jul 2022 23.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
At close: 01:37PM EDT
Full screen
Previous close0.0500
Open0.0500
Bid0.0500
Ask0.0500
Strike23.00
Expiry date2022-07-15
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume1
Open interest102
  • Zacks

    Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

    Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

  • GlobeNewswire

    Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

    NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announces Anavex’s very first Educational Video News Release, which can be accessed via Anavex's newsroom. To

  • Zacks

    How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%

    The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.